OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system
Xiangping Wu, Xikui Lu, Zhenting Wang, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 10, pp. 975-984
Closed Access | Times Cited: 7
Xiangping Wu, Xikui Lu, Zhenting Wang, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 10, pp. 975-984
Closed Access | Times Cited: 7
Showing 7 citing articles:
Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study
Yoichi Nakayama, Akira Ōnishi, Wataru Yamamoto, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Yoichi Nakayama, Akira Ōnishi, Wataru Yamamoto, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018–2023
Jinger Lin, X.Y. Chen, Min Luo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Jinger Lin, X.Y. Chen, Min Luo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database
Jiancheng Qian, Shuohan Zhang, Cheng Jiang
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Jiancheng Qian, Shuohan Zhang, Cheng Jiang
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database
Xiang Li, Shu Wen Wang, Zhijie Zhang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Xiang Li, Shu Wen Wang, Zhijie Zhang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Earlier onset of acute venous thromboembolism with upadacitinib compared with tofacitinib during Janus kinase inhibitor therapy
Jeffrey A. Lowell, G.V.R.K. Sharma, Keith Sultan
Research and Practice in Thrombosis and Haemostasis (2024) Vol. 8, Iss. 4, pp. 102440-102440
Open Access | Times Cited: 1
Jeffrey A. Lowell, G.V.R.K. Sharma, Keith Sultan
Research and Practice in Thrombosis and Haemostasis (2024) Vol. 8, Iss. 4, pp. 102440-102440
Open Access | Times Cited: 1
Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database
Jiayu Yuan, Hongxia Lu, Xulei Zuo, et al.
Pharmacoepidemiology and Drug Safety (2024) Vol. 33, Iss. 10
Open Access | Times Cited: 1
Jiayu Yuan, Hongxia Lu, Xulei Zuo, et al.
Pharmacoepidemiology and Drug Safety (2024) Vol. 33, Iss. 10
Open Access | Times Cited: 1
Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system
Zhu Zhou, Mingjuan Liu, Hanlin Zhang, et al.
Expert Opinion on Drug Safety (2024), pp. 1-8
Closed Access
Zhu Zhou, Mingjuan Liu, Hanlin Zhang, et al.
Expert Opinion on Drug Safety (2024), pp. 1-8
Closed Access
